Table 1. Baseline Characteristics.

Variable	Placebo (n=759)	Fluconazole (n=760)	Overall (n=1519)
Sex          Male n (%)	251 (33.1%)	286 (37.6%)	537 (35.4%)
Female n (%)	508 (66.9%)	474 (62.4%)	982 (64.6%)
Age (years Mean (s.d.))	35.8 (8.8)	35.9 (9.1)	35.8 (9.0)
Age (grouped)    <25	47 (6.2%)	58 (7.6%)	105 (6.9%)
25-34	323 (42.6%)	306 (40.3%)	629 (41.4%)
35-44	270 (35.6%)	269 (35.4%)	539 (35.5%)
45 +	119 (15.7%)	127 (16.7%)	246 (16.2%)
CD4 count (median (IQR))	112 (48 – 157)	110 ( 45 – 160)	111 (46 – 159)
CD4 count (grouped)
150 – 199	231 (30.4%)	237 (31.2%)	468 (30.8%)
100 – 149	185 (24.4%)	168 (22.1%)	353 (23.2%)
50 – 99	150 (19.8%)	152 (20.0%)	302 (19.9%)
1 - 49	193 (25.4%)	203 (26.7%)	396 (26.1%)
WHO stage       1	20 (2.6%)	18 (2.4%)	38 (2.5%)
2	164 (21.6%)	175 (23.0%)	339 (22.3%)
3	524 (69.0%)	506 (66.6%)	1030 (67.8%)
4	51 (6.7%)	61 (8.0%)	112 (7.4%)